{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:22:09Z","timestamp":1754396529783},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shire International GmbH, a member of Takeda group","award":["IIR-DEU-002334","IIR-DEU-002334"],"award-info":[{"award-number":["IIR-DEU-002334","IIR-DEU-002334"]}]},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiac manifestation of classical Fabry disease (cFD) varies with sex and presence of left ventricular hypertrophy. p.D313Y\/p.A143T variants (vFD) represent milder late-onset phenotypes, however, data on vFD are scarce. Patients with FD (cFD\u2009=\u200937;vFD\u2009=\u200914) and 14 healthy controls underwent 1.5\u00a0T CMR including Cine, LGE, native T1 mapping(nT1) and myocardial strain(CMR-FT). CMR-FT was assessed using ventricular longitudinal, circumferential, radial (LV-GLS\/RV-GLS, LV-GCS\/LV-GRS), and atrial longitudinal strain (LA\/RA<jats:sub>Total<\/jats:sub>, LA\/RA<jats:sub>Conduit<\/jats:sub>, LA\/RA<jats:sub>Booster<\/jats:sub>). In cFD reduced myocardial strain (LV-GLS: \u221220\u2009\u00b1\u20094 vs. \u221224\u2009\u00b1\u20093%,<jats:italic>p<\/jats:italic>\u2009=\u20090.007; LV-GCS: \u221220\u2009\u00b1\u20094 vs. \u221226\u2009\u00b1\u20094%,<jats:italic>p<\/jats:italic>\u2009=\u20090.002, LA\u00a0<jats:sub>Total<\/jats:sub>\u00a0-GLS: 29\u2009\u00b1\u200910 vs. 37\u2009\u00b1\u20096%,<jats:italic>p<\/jats:italic>\u2009=\u20090.007; LA\u00a0<jats:sub>Conduit<\/jats:sub>\u00a0-GLS: 15\u2009\u00b1\u200910 vs. 23\u2009\u00b1\u20095%,<jats:italic>p<\/jats:italic>\u2009=\u20090.003) and nT1 values (951\u2009\u00b1\u200951\u00a0ms vs. 1036\u2009\u00b1\u200920\u00a0ms, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were observed compared to controls. In vFD findings were comparable to controls. LV-GCS provided the closest Area under the curve (AUC) to nT1 (0.84 vs. 0.92, <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) for discrimination of cFD versus controls. Significantly lower LV-GLS\/LV-GCS was found in male compared to female cFD (\u221219\u2009\u00b1\u20094 vs. \u221222\u2009\u00b1\u20094%, <jats:italic>p<\/jats:italic>\u2009=\u20090.03). In six non-hypertrophied female cFD with normal nT1 LA<jats:sub>Total<\/jats:sub>\u00a0-GLS was the only discriminating parameter with an accuracy of 86%. LV-GLS, LV-GCS and LA<jats:sub>Total<\/jats:sub>\u00a0-GLS can detect impaired cardiac mechanics of cFD besides nT1. LA<jats:sub>Total<\/jats:sub>\u00a0-GLS might identify non-hypertrophied female cFD. Variants p.D313Y\/p.A143T did not reveal cardiac involvement by multiparametric CMR.\n<\/jats:p>","DOI":"10.1038\/s41598-023-32464-0","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T10:02:42Z","timestamp":1681120962000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of classical Fabry and its p.D313Y and p.A143T variants by cardiac T1 mapping, LGE and feature tracking myocardial strain"],"prefix":"10.1038","volume":"13","author":[{"given":"Maxim","family":"Avanesov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahid","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja Friederike","family":"K\u00f6hn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enver","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersin","family":"Cavus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"32464_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19123726","volume":"19","author":"G Duro","year":"2018","unstructured":"Duro, G. et al. Mutations in the GLA gene and LysoGb3: Is it really Anderson-Fabry disease\u202f?. Int. J. Mol. Sci. 19, 1\u201313 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"32464_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","volume":"26","author":"F Weidemann","year":"2005","unstructured":"Weidemann, F. et al. The variation of morphological and functional cardiac manifestation in Fabry disease: Potential implications for the time course of the disease. Eur. Heart J. 26, 1221\u20131227 (2005).","journal-title":"Eur. Heart J."},{"key":"32464_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","volume":"57","author":"MR Patel","year":"2011","unstructured":"Patel, M. R. et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. JACC 57, 1093\u20131099 (2011).","journal-title":"JACC"},{"key":"32464_CR4","first-page":"1","volume":"5","author":"M Arends","year":"2016","unstructured":"Arends, M. et al. Characterization of classical and nonclassical Fabry disease: A multicenter study. J. Am. Soc. Neprology 5, 1\u201311 (2016).","journal-title":"J. Am. Soc. Neprology"},{"key":"32464_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017098","author":"K Koulousios","year":"2017","unstructured":"Koulousios, K. et al. Fabry disease due to D313Y and novel GLA mutations. BMJ Open https:\/\/doi.org\/10.1136\/bmjopen-2017-017098 (2017).","journal-title":"BMJ Open"},{"key":"32464_CR6","doi-asserted-by":"crossref","unstructured":"du Moulin, M. et al. The mutation p.D313Y is associated with organ manifestation in Fabry disease. Clin. Genet. 92, (2017).","DOI":"10.1111\/cge.13007"},{"key":"32464_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/heartjnl-2019-315933","volume":"106","author":"K Valtola","year":"2020","unstructured":"Valtola, K. et al. Cardiomyopathy associated with the Ala143Thr variant of the \u03b1-galactosidase A gene. Heart 106, 609\u2013615 (2020).","journal-title":"Heart"},{"key":"32464_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann, F. et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119, 524\u2013529 (2009).","journal-title":"Circulation"},{"key":"32464_CR9","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","volume":"24","author":"JCC Moon","year":"2003","unstructured":"Moon, J. C. C. et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur. Heart J. 24, 2151\u20132155 (2003).","journal-title":"Eur. Heart J."},{"key":"32464_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","volume":"6","author":"DM Sado","year":"2013","unstructured":"Sado, D. M. et al. Identification and assessment of anderson-fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ. Cardiovasc. Imaging 6, 392\u2013398 (2013).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"32464_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.007168","volume":"11","author":"S Nordin","year":"2018","unstructured":"Nordin, S. et al. Cardiac phenotype of prehypertrophic Fabry disease. Circ. Cardiovasc. Imaging 11, e007168 (2018).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"32464_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12968-016-0269-7","volume":"18","author":"G Pedrizzetti","year":"2016","unstructured":"Pedrizzetti, G., Claus, P., Kilner, P. J. & Nagel, E. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J. Cardiovasc. Magn. Reson. 18, 1\u201312 (2016).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"32464_CR13","first-page":"99","volume":"16","author":"S Pica","year":"2014","unstructured":"Pica, S. et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson. 16, 99 (2014).","journal-title":"J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson."},{"key":"32464_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/heartjnl-2018-313699","volume":"105","author":"R Vijapurapu","year":"2019","unstructured":"Vijapurapu, R. et al. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease. Heart 105, 470\u2013476 (2019).","journal-title":"Heart"},{"key":"32464_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12968-019-0557-0","volume":"21","author":"S Mathur","year":"2019","unstructured":"Mathur, S. et al. Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: Relationship to T1 mapping, late gadolinium enhancement and hypertrophy. J. Cardiovasc. Magn. Reson. 21, 45 (2019).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"32464_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12968-015-0111-7","volume":"17","author":"N Kawel-Boehm","year":"2015","unstructured":"Kawel-Boehm, N. et al. Normal values for cardiovascular magnetic resonance in adults and children. J. Cardiovasc. Magn. Reson. 17, 29 (2015).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"32464_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1373\/clinchem.2014.231530","volume":"61","author":"R Body","year":"2015","unstructured":"Body, R. et al. High-sensitivity cardiac troponin t concentrations below the limit of detection to exclude acute myocardial infarction: A prospective evaluation. Clin. Chem. 61, 983\u2013989 (2015).","journal-title":"Clin. Chem."},{"key":"32464_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution o. Eur. Heart J. 37, 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"key":"32464_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas, J. et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 9, e1003632 (2013).","journal-title":"PLoS Genet."},{"key":"32464_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Schulz-Menger","year":"2020","unstructured":"Schulz-Menger, J. et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance\u20132020 update: Society for cardiovascular magnetic resonance (SCMR): Board of trustees task force on standardized post-processing. J. Cardiovasc. Magn. Reson. 22, 1\u201322 (2020).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"32464_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12968-016-0269-7","volume":"18","author":"G Pedrizzetti","year":"2016","unstructured":"Pedrizzetti, G., Claus, P., Kilner, P. J. & Nagel, E. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J. Cardiovasc. Magn. Reson. 18, 51 (2016).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"32464_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12968-014-0060-6","volume":"16","author":"JT Kowallick","year":"2014","unstructured":"Kowallick, J. T. et al. Quantification of left atrial strain and strain rate using cardiovascular magnetic resonance myocardial feature tracking: A feasibility study. J. Cardiovasc. Magn. Reson. 16, 1\u20139 (2014).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"32464_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jcmg.2012.09.018","volume":"6","author":"G Moravsky","year":"2013","unstructured":"Moravsky, G. et al. Myocardial fibrosis in hypertrophic cardiomyopathy: Accurate reflection of histopathological findings by CMR. JACC. Cardiovasc. Imaging 6, 587\u2013596 (2013).","journal-title":"JACC. Cardiovasc. Imaging"},{"key":"32464_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/0471445428","volume-title":"Statistical methods for rates and proportions","author":"J Fleiss","year":"2003","unstructured":"Fleiss, J., Levin, B. & Paik, M. Statistical methods for rates and proportions 3rd edn. (Wiley, 2003).","edition":"3"},{"key":"32464_CR25","first-page":"301","volume":"2","author":"DA Morris","year":"2014","unstructured":"Morris, D. A. et al. Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: Left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status. Int. J. Cardiovasc. Imaging 2, 301\u2013313 (2014).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"32464_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/echo.13829","volume":"35","author":"MC Saccheri","year":"2018","unstructured":"Saccheri, M. C. et al. Comparison of left atrial size and function in hypertrophic cardiomyopathy and in Fabry disease with left ventricular hypertrophy. Echocardiography 35, 643\u2013650 (2018).","journal-title":"Echocardiography"},{"key":"32464_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/echo.13496","volume":"34","author":"F Labombarda","year":"2017","unstructured":"Labombarda, F., Saloux, E., Milesi, G. & Bienvenu, B. Loss of base-to-apex circumferential strain gradient: A specific pattern of Fabry cardiomyopathy?. Echocardiography 34, 504\u2013510 (2017).","journal-title":"Echocardiography"},{"key":"32464_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","volume":"12","author":"S Nordin","year":"2019","unstructured":"Nordin, S. et al. Proposed stages of myocardial phenotype development in Fabry disease. JACC. Cardiovasc. Imaging 12, 1673\u20131683 (2019).","journal-title":"JACC. Cardiovasc. Imaging"},{"key":"32464_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.hfc.2008.03.013","volume":"4","author":"PP Sengupta","year":"2008","unstructured":"Sengupta, P. P. & Narula, J. Reclassifying heart failure: predominantly subendocardial, subepicardial, and transmural. Heart Fail. Clin. 4, 379\u2013382 (2008).","journal-title":"Heart Fail. Clin."},{"key":"32464_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1750-1172-8-116","volume":"8","author":"F Weidemann","year":"2013","unstructured":"Weidemann, F. et al. Fibrosis: A key feature of Fabry disease with potential therapeutic implications. Orphanet J. Rare Dis. 8, 116 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"32464_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ejcts.2005.06.043","volume":"28","author":"RH Anderson","year":"2005","unstructured":"Anderson, R. H., Ho, S. Y., Redmann, K., Sanchez-Quintana, D. & Lunkenheimer, P. P. The anatomical arrangement of the myocardial cells making up the ventricular mass. Eur. J. cardio-thoracic Surg Off. J. Eur. Assoc. Cardio-thoracic Surg. 28, 517\u2013525 (2005).","journal-title":"Eur. J. cardio-thoracic Surg Off. J. Eur. Assoc. Cardio-thoracic Surg."},{"key":"32464_CR32","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/hrt.2010.196162","volume":"96","author":"C Chimenti","year":"2010","unstructured":"Chimenti, C., Russo, M. A. & Frustaci, A. Atrial biopsy evidence of Fabry disease causing lone atrial fibrillation. Heart 96, 1782\u20131784 (2010).","journal-title":"Heart"},{"key":"32464_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.carpath.2009.05.003","volume":"19","author":"MN Sheppard","year":"2010","unstructured":"Sheppard, M. N. et al. A detailed pathologic examination of heart tissue from three older patients with Anderson\u2013Fabry disease on enzyme replacement therapy. Cardiovasc. Pathol. 19, 293\u2013301 (2010).","journal-title":"Cardiovasc. Pathol."},{"key":"32464_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.echo.2016.10.014","volume":"30","author":"M Pichette","year":"2017","unstructured":"Pichette, M. et al. Impaired left atrial function in Fabry disease: A longitudinal speckle-tracking echocardiography study. J. Am. Soc. Echocardiogr. 30, 170-179.e2 (2017).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"32464_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","volume":"4","author":"M Niemann","year":"2011","unstructured":"Niemann, M. et al. Differences in fabry cardiomyopathy between female and male patients: Consequences for diagnostic assessment. JACC Cardiovasc. Imaging 4, 592\u2013601 (2011).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"32464_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCIMAGING.119.009430","volume":"12","author":"S Nordin","year":"2019","unstructured":"Nordin, S. et al. Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ. Cardiovasc. Imaging 12, 1\u20139 (2019).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"32464_CR37","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/jimd.12240","volume":"43","author":"G Effraimidis","year":"2020","unstructured":"Effraimidis, G., Rasmussen, \u00c5. K., Bundgaard, H., S\u00f8rensen, S. S. & Feldt-Rasmussen, U. Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review. J. Inherit. Metab. Dis. 43, 922\u2013933 (2020).","journal-title":"J. Inherit. Metab. Dis."},{"key":"32464_CR38","doi-asserted-by":"crossref","unstructured":"Godel, T. et al. Assessment of peripheral nervous system alterations in patients with the Fabry related GLA-variant p.A143T. Diagnost. Basel, Switzerland 10, (2020).","DOI":"10.3390\/diagnostics10121027"},{"key":"32464_CR39","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1007\/s00330-018-5538-4","volume":"28","author":"M Barreiro-P\u00e9rez","year":"2018","unstructured":"Barreiro-P\u00e9rez, M. et al. Left ventricular global myocardial strain assessment comparing the reproducibility of four commercially available CMR-feature tracking algorithms. Eur. Radiol. 28, 5137\u20135147 (2018).","journal-title":"Eur. Radiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32464-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T10:08:42Z","timestamp":1681121322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32464-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32464"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32464-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"11 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5809"}}